Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease

Alzheimer's disease (AD) is a chronic, progressive brain degenerative disease that is common in the elderly. So far, there is no effective treatment. The multi-target-directed ligands (MTDLs) strategy has been recognised as the most promising approach due to the complexity of the pathogenesis o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of enzyme inhibition and medicinal chemistry 2023-12, Vol.38 (1), p.2231661-2231661
Main Authors: Zhou, Yi, He, Ying, Teng, Xue, Mi, Jing, Yang, Jing, Wei, Rongrui, Liu, Wenmin, Ma, Qinge, Tan, Zhenghuai, Sang, Zhipei
Format: Article
Language:English
Subjects:
Acids
Alzheimer's disease
Biological activity
Brain research
Chinese medicine
Cognitive ability
Donepezil
drug-likeness
Education
Enzymes
Hybrids
Hypotheses
Inflammation
Ligands
multi-functional agent
Neurodegenerative diseases
Neuroprotection
Pathogenesis
Pharmaceutical sciences
Research Paper
Rivastigmine
Salicylic acid
salicylic acid-donepezil-rivastigmine hybrids
Scopolamine
scopolamine-induced AD model
Toxicology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c563t-fb835333e3e0a225bacded85bdabfaff2a037334ffb2f0164084447799f96b143
cites cdi_FETCH-LOGICAL-c563t-fb835333e3e0a225bacded85bdabfaff2a037334ffb2f0164084447799f96b143
container_end_page 2231661
container_issue 1
container_start_page 2231661
container_title Journal of enzyme inhibition and medicinal chemistry
container_volume 38
creator Zhou, Yi
He, Ying
Teng, Xue
Mi, Jing
Yang, Jing
Wei, Rongrui
Liu, Wenmin
Ma, Qinge
Tan, Zhenghuai
Sang, Zhipei
description Alzheimer's disease (AD) is a chronic, progressive brain degenerative disease that is common in the elderly. So far, there is no effective treatment. The multi-target-directed ligands (MTDLs) strategy has been recognised as the most promising approach due to the complexity of the pathogenesis of AD. Herein, novel salicylic acid-donepezil-rivastigmine hybrids were designed and synthesised. The bioactivity results exhibited that 5a was a reversible and selective eqBChE inhibitor (IC 50  = 0.53 μM), and the docking provided the possible mechanism. Compound 5a also displayed potential anti-inflammatory effects and significant neuroprotective effect. Moreover, 5a exhibited favourable stabilities in artificial gastrointestinal solution and plasma. Finally, 5a demonstrated potential cognitive improvement in scopolamine-induced cognitive dysfunction. Hence, 5a was a potential multifunctional lead compound against AD.
doi_str_mv 10.1080/14756366.2023.2231661
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10327518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_01e902f90d2041f1bf78b8a7c5596af2</doaj_id><sourcerecordid>2917548984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-fb835333e3e0a225bacded85bdabfaff2a037334ffb2f0164084447799f96b143</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIlsJPAFniAJcs_oqTnGhVvipV4gJnaxKPd1058WIni7Z3_jde9kOUAwfL9sybN_PsVxQvGV0w2tB3TNaVEkotOOViwblgSrFHxfkuXipRy8ens1JnxbOU7ijljDP5tDjLaSZz-Xnx6wNu0If1gONEgiVjyFeSwLt-mxeB3pnShBHXeO98Gd0G0uSWgxuRrLZddCYRSGSY_eTsPPaTCyN4AsvMl4gNkUwrJFNEmI4trvz9Ct2A8U0ixiWEhM-LJxZ8wheH_aL4_unjt-sv5e3XzzfXV7dln4edSts1ohJCoEAKnFcd9AZNU3UGOgvWcqCiFkJa23FLmZK0kVLWddvaVnVMioviZs9rAtzpdXQDxK0O4PSfQIhLDXFyvUdNGbaU25YaTiWzrLN10zVQ91XVKrA8c73fc63nbkDTZ3UR_APSh5nRrfQybDSjgtcVazLD2wNDDD9mTJMeXOrRexgxzEnzrJbXomK7Zq__gd6FOeaXzqiW1ZVs2mYnr9qj-hhSimhP0zCqd67RR9fonWv0wTW57tXfUk5VR5tkwOUe4Mb8pQP8DNEbPcHWh2gjjL1LWvy_x28TkNRZ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2917548984</pqid></control><display><type>article</type><title>Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><creator>Zhou, Yi ; He, Ying ; Teng, Xue ; Mi, Jing ; Yang, Jing ; Wei, Rongrui ; Liu, Wenmin ; Ma, Qinge ; Tan, Zhenghuai ; Sang, Zhipei</creator><creatorcontrib>Zhou, Yi ; He, Ying ; Teng, Xue ; Mi, Jing ; Yang, Jing ; Wei, Rongrui ; Liu, Wenmin ; Ma, Qinge ; Tan, Zhenghuai ; Sang, Zhipei</creatorcontrib><description>Alzheimer's disease (AD) is a chronic, progressive brain degenerative disease that is common in the elderly. So far, there is no effective treatment. The multi-target-directed ligands (MTDLs) strategy has been recognised as the most promising approach due to the complexity of the pathogenesis of AD. Herein, novel salicylic acid-donepezil-rivastigmine hybrids were designed and synthesised. The bioactivity results exhibited that 5a was a reversible and selective eqBChE inhibitor (IC 50  = 0.53 μM), and the docking provided the possible mechanism. Compound 5a also displayed potential anti-inflammatory effects and significant neuroprotective effect. Moreover, 5a exhibited favourable stabilities in artificial gastrointestinal solution and plasma. Finally, 5a demonstrated potential cognitive improvement in scopolamine-induced cognitive dysfunction. Hence, 5a was a potential multifunctional lead compound against AD.</description><identifier>ISSN: 1475-6366</identifier><identifier>EISSN: 1475-6374</identifier><identifier>DOI: 10.1080/14756366.2023.2231661</identifier><identifier>PMID: 37414563</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Acids ; Alzheimer's disease ; Biological activity ; Brain research ; Chinese medicine ; Cognitive ability ; Donepezil ; drug-likeness ; Education ; Enzymes ; Hybrids ; Hypotheses ; Inflammation ; Ligands ; multi-functional agent ; Neurodegenerative diseases ; Neuroprotection ; Pathogenesis ; Pharmaceutical sciences ; Research Paper ; Rivastigmine ; Salicylic acid ; salicylic acid-donepezil-rivastigmine hybrids ; Scopolamine ; scopolamine-induced AD model ; Toxicology</subject><ispartof>Journal of enzyme inhibition and medicinal chemistry, 2023-12, Vol.38 (1), p.2231661-2231661</ispartof><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2023</rights><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2023 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-fb835333e3e0a225bacded85bdabfaff2a037334ffb2f0164084447799f96b143</citedby><cites>FETCH-LOGICAL-c563t-fb835333e3e0a225bacded85bdabfaff2a037334ffb2f0164084447799f96b143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327518/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2917548984?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27502,27924,27925,37012,37013,44590,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37414563$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>He, Ying</creatorcontrib><creatorcontrib>Teng, Xue</creatorcontrib><creatorcontrib>Mi, Jing</creatorcontrib><creatorcontrib>Yang, Jing</creatorcontrib><creatorcontrib>Wei, Rongrui</creatorcontrib><creatorcontrib>Liu, Wenmin</creatorcontrib><creatorcontrib>Ma, Qinge</creatorcontrib><creatorcontrib>Tan, Zhenghuai</creatorcontrib><creatorcontrib>Sang, Zhipei</creatorcontrib><title>Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease</title><title>Journal of enzyme inhibition and medicinal chemistry</title><addtitle>J Enzyme Inhib Med Chem</addtitle><description>Alzheimer's disease (AD) is a chronic, progressive brain degenerative disease that is common in the elderly. So far, there is no effective treatment. The multi-target-directed ligands (MTDLs) strategy has been recognised as the most promising approach due to the complexity of the pathogenesis of AD. Herein, novel salicylic acid-donepezil-rivastigmine hybrids were designed and synthesised. The bioactivity results exhibited that 5a was a reversible and selective eqBChE inhibitor (IC 50  = 0.53 μM), and the docking provided the possible mechanism. Compound 5a also displayed potential anti-inflammatory effects and significant neuroprotective effect. Moreover, 5a exhibited favourable stabilities in artificial gastrointestinal solution and plasma. Finally, 5a demonstrated potential cognitive improvement in scopolamine-induced cognitive dysfunction. Hence, 5a was a potential multifunctional lead compound against AD.</description><subject>Acids</subject><subject>Alzheimer's disease</subject><subject>Biological activity</subject><subject>Brain research</subject><subject>Chinese medicine</subject><subject>Cognitive ability</subject><subject>Donepezil</subject><subject>drug-likeness</subject><subject>Education</subject><subject>Enzymes</subject><subject>Hybrids</subject><subject>Hypotheses</subject><subject>Inflammation</subject><subject>Ligands</subject><subject>multi-functional agent</subject><subject>Neurodegenerative diseases</subject><subject>Neuroprotection</subject><subject>Pathogenesis</subject><subject>Pharmaceutical sciences</subject><subject>Research Paper</subject><subject>Rivastigmine</subject><subject>Salicylic acid</subject><subject>salicylic acid-donepezil-rivastigmine hybrids</subject><subject>Scopolamine</subject><subject>scopolamine-induced AD model</subject><subject>Toxicology</subject><issn>1475-6366</issn><issn>1475-6374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk1v1DAQjRCIlsJPAFniAJcs_oqTnGhVvipV4gJnaxKPd1058WIni7Z3_jde9kOUAwfL9sybN_PsVxQvGV0w2tB3TNaVEkotOOViwblgSrFHxfkuXipRy8ens1JnxbOU7ijljDP5tDjLaSZz-Xnx6wNu0If1gONEgiVjyFeSwLt-mxeB3pnShBHXeO98Gd0G0uSWgxuRrLZddCYRSGSY_eTsPPaTCyN4AsvMl4gNkUwrJFNEmI4trvz9Ct2A8U0ixiWEhM-LJxZ8wheH_aL4_unjt-sv5e3XzzfXV7dln4edSts1ohJCoEAKnFcd9AZNU3UGOgvWcqCiFkJa23FLmZK0kVLWddvaVnVMioviZs9rAtzpdXQDxK0O4PSfQIhLDXFyvUdNGbaU25YaTiWzrLN10zVQ91XVKrA8c73fc63nbkDTZ3UR_APSh5nRrfQybDSjgtcVazLD2wNDDD9mTJMeXOrRexgxzEnzrJbXomK7Zq__gd6FOeaXzqiW1ZVs2mYnr9qj-hhSimhP0zCqd67RR9fonWv0wTW57tXfUk5VR5tkwOUe4Mb8pQP8DNEbPcHWh2gjjL1LWvy_x28TkNRZ</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Zhou, Yi</creator><creator>He, Ying</creator><creator>Teng, Xue</creator><creator>Mi, Jing</creator><creator>Yang, Jing</creator><creator>Wei, Rongrui</creator><creator>Liu, Wenmin</creator><creator>Ma, Qinge</creator><creator>Tan, Zhenghuai</creator><creator>Sang, Zhipei</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202312</creationdate><title>Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease</title><author>Zhou, Yi ; He, Ying ; Teng, Xue ; Mi, Jing ; Yang, Jing ; Wei, Rongrui ; Liu, Wenmin ; Ma, Qinge ; Tan, Zhenghuai ; Sang, Zhipei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-fb835333e3e0a225bacded85bdabfaff2a037334ffb2f0164084447799f96b143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acids</topic><topic>Alzheimer's disease</topic><topic>Biological activity</topic><topic>Brain research</topic><topic>Chinese medicine</topic><topic>Cognitive ability</topic><topic>Donepezil</topic><topic>drug-likeness</topic><topic>Education</topic><topic>Enzymes</topic><topic>Hybrids</topic><topic>Hypotheses</topic><topic>Inflammation</topic><topic>Ligands</topic><topic>multi-functional agent</topic><topic>Neurodegenerative diseases</topic><topic>Neuroprotection</topic><topic>Pathogenesis</topic><topic>Pharmaceutical sciences</topic><topic>Research Paper</topic><topic>Rivastigmine</topic><topic>Salicylic acid</topic><topic>salicylic acid-donepezil-rivastigmine hybrids</topic><topic>Scopolamine</topic><topic>scopolamine-induced AD model</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>He, Ying</creatorcontrib><creatorcontrib>Teng, Xue</creatorcontrib><creatorcontrib>Mi, Jing</creatorcontrib><creatorcontrib>Yang, Jing</creatorcontrib><creatorcontrib>Wei, Rongrui</creatorcontrib><creatorcontrib>Liu, Wenmin</creatorcontrib><creatorcontrib>Ma, Qinge</creatorcontrib><creatorcontrib>Tan, Zhenghuai</creatorcontrib><creatorcontrib>Sang, Zhipei</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Yi</au><au>He, Ying</au><au>Teng, Xue</au><au>Mi, Jing</au><au>Yang, Jing</au><au>Wei, Rongrui</au><au>Liu, Wenmin</au><au>Ma, Qinge</au><au>Tan, Zhenghuai</au><au>Sang, Zhipei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease</atitle><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle><addtitle>J Enzyme Inhib Med Chem</addtitle><date>2023-12</date><risdate>2023</risdate><volume>38</volume><issue>1</issue><spage>2231661</spage><epage>2231661</epage><pages>2231661-2231661</pages><issn>1475-6366</issn><eissn>1475-6374</eissn><abstract>Alzheimer's disease (AD) is a chronic, progressive brain degenerative disease that is common in the elderly. So far, there is no effective treatment. The multi-target-directed ligands (MTDLs) strategy has been recognised as the most promising approach due to the complexity of the pathogenesis of AD. Herein, novel salicylic acid-donepezil-rivastigmine hybrids were designed and synthesised. The bioactivity results exhibited that 5a was a reversible and selective eqBChE inhibitor (IC 50  = 0.53 μM), and the docking provided the possible mechanism. Compound 5a also displayed potential anti-inflammatory effects and significant neuroprotective effect. Moreover, 5a exhibited favourable stabilities in artificial gastrointestinal solution and plasma. Finally, 5a demonstrated potential cognitive improvement in scopolamine-induced cognitive dysfunction. Hence, 5a was a potential multifunctional lead compound against AD.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>37414563</pmid><doi>10.1080/14756366.2023.2231661</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-6366
ispartof Journal of enzyme inhibition and medicinal chemistry, 2023-12, Vol.38 (1), p.2231661-2231661
issn 1475-6366
1475-6374
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10327518
source Open Access: PubMed Central; Taylor & Francis Open Access; Publicly Available Content Database
subjects Acids
Alzheimer's disease
Biological activity
Brain research
Chinese medicine
Cognitive ability
Donepezil
drug-likeness
Education
Enzymes
Hybrids
Hypotheses
Inflammation
Ligands
multi-functional agent
Neurodegenerative diseases
Neuroprotection
Pathogenesis
Pharmaceutical sciences
Research Paper
Rivastigmine
Salicylic acid
salicylic acid-donepezil-rivastigmine hybrids
Scopolamine
scopolamine-induced AD model
Toxicology
title Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20novel%20salicylic%20acid-donepezil-rivastigmine%20hybrids%20as%20multifunctional%20agents%20for%20the%20treatment%20of%20Alzheimer's%20disease&rft.jtitle=Journal%20of%20enzyme%20inhibition%20and%20medicinal%20chemistry&rft.au=Zhou,%20Yi&rft.date=2023-12&rft.volume=38&rft.issue=1&rft.spage=2231661&rft.epage=2231661&rft.pages=2231661-2231661&rft.issn=1475-6366&rft.eissn=1475-6374&rft_id=info:doi/10.1080/14756366.2023.2231661&rft_dat=%3Cproquest_pubme%3E2917548984%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c563t-fb835333e3e0a225bacded85bdabfaff2a037334ffb2f0164084447799f96b143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2917548984&rft_id=info:pmid/37414563&rfr_iscdi=true